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Cell-based treatments of central nervous system (CNS) disorders
are an emerging paradigm in experimental medicine. Given the ana-
tomical and functional complexity of the mammalian brain, the
tempting concept of simply replacing lost or critically affected brain
tissue by stem cell transplants appeared difficult to realise. Therapeu-
tic approaches now try to support endogenous regeneration and
reorganisation, as well as to prevent secondary damage. This is
achieved by paracrine and other so-called bystander effects. Preclini-
cal research revealed a broad spectrum of such mechanisms for two
of the most frequently investigated cell populations: mesenchymal
stem cells (MSCs) and neural stem cells (NSCs). Although therapeuti-
cally relevant systemic effects of MSC and NSC transplantation have
been identified, targeted delivery of cells to the brain tissue is consid-
ered important to achieve an optimal outcome in CNS disorders.
Clinical trials are subject to a number of logistical and medical
requirements. These ensure maximum patient safety and the best pos-
sible standard of treatment, but cause significant design differences
when compared to preclinical studies using stem cells [1]. For instance,
cell populations are predominantly applied intravenously in clinics
althoughmore targeted approaches such as stereotaxic transplantation
are often more effective in animal experiments. On the other hand,
repeated stereotaxic cell administration to place stem cell deposits in
the target area is not only logistically challenging, but may increase the
risk of secondary brain damage in humans [2]. Alternative approaches
such as intra-arterial (carotid) stem cell administration may achieve
more targeted cell delivery to the brain while being combined with
state-of-the-art recanalization approaches in stroke.E-mail address: johannes.boltze@warwick.ac.uk (J. Boltze).
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ulations such as MSCs bears the risk of secondary cerebral vessel
occlusion and microlesions [3]. To overcome these limitations, stem
cell populations with enhanced migratory abilities are required.
These cells would be able to reach the target tissue in greater num-
bers after systemic or intranasal administration and would egress
from blood vessels more swiftly. Two recent publications in this issue
of EBioMedicine report significant progress in exactly that direction
(Fig. 1).
The first manuscript [4] describes the isolation of highly migrating
NSC and MSC subpopulations from murine and human cell popula-
tions. These subpopulations (sNSC and sMSC, respectively) were able
to migrate faster and over longer distances. Detailed transcriptome
analyses of these populations revealed an increased expression of
podoplanin (PDPN), a factor crucial for regulating stem cell migratory
abilities, in the cells. The cells showed superior therapeutic abilities
when applied in in vitro models of glioblastoma and an animal model
of Alzheimer’s disease. Importantly, superior migration abilities were
induced by PDPN mRNA transfection allowing for transient modifica-
tion of the cells. The second manuscript [5] reported that pre-treat-
ment with the cationic molecule polyethylenimine (PEI) increases
CCR4 expression on MSCs. Subsequent suppression of adhesion mole-
cule receptors effectively prevented pulmonary filtering, a well-known
phenomenon after intravenous delivery of large cell populations such
as MSCs, and increased cell homing to the brain. MSC viability and
therapeutically essential functions such as immunomodulation and dif-
ferentiation potential remained unchanged. PEI-modified MSCs were
successfully applied in animal models of cerebrovascular disorders,
brain excitotoxicity and malignant CNS neoplasm. Those findings are
highly relevant to both basic science and clinical medicine for the fol-
lowing reasons.
First, these approaches might be used to augment therapeutically
relevant mechanisms of other adult cell populations such as mononu-
clear cells (MNCs) for which a direct cell-cell interaction in the thera-
peutically targeted brain tissue is required [6]. The concepts may also
help to improve therapeutic application of other cell populations that
rely on long-distance targeted migration within the brain such as
glial-restricted progenitor cells being used to treat white matterder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
Fig. 1. Mechanisms to increase stem cell migration abilities. The targeted delivery of
neural stem cells (NSCs) and mesenchymal stem cells (MSCs) to damaged brain areas
is a promising tool to improve post-lesional regeneration and reorganization, and to
prevent secondary damage. (A) Current state of the art delivery of cell delivery through
stereotaxic transplantation or intra-carotid administration can cause complications
and bears the risk of additional brain damage. (B) MSC, modified to express enhanced
levels of podoplanin (PDPN), showed significantly increased migration abilities. The
MSCs migrated faster and over longer distances, which resulted in enhanced therapeu-
tic abilities in an animal model of Alzheimer’s disease after intranasal application. In a
glioblastoma mouse model, MSCs also migrated more efficiently after stereotactic
transplantation into the contralateral hemisphere (not shown) (C) Another promising
approach is the pre-treatment of MSCs with polyethylenimine (PEI) that increased
CCR4 surface expression and blocked adhesion receptors. This was shown to prevent
pulmonary MSC filtering and increased cell homing to the brain without changing
MSC viability or therapeutically relevant functions.
2 J. Boltze et al. / EBioMedicine 60 (2020) 103022damage. Bone marrow-derived MNC therapies for CNS disorders are
already in early-stage clinical evaluation and upcoming, efficacy-ori-
ented studies might benefit from these findings.
Second, the reported applications are well in line with current
recommendations in the field of translational stem cell research. For
instance, increased homing and vessel egress abilities increase com-
parability with recanalization approaches in stroke, a central require-
ment for future cytoprotective therapies in stroke [7]. In parallel,
compatibility with cell labelling techniques based on ferromagnetic
nanoparticles provide excellent options for non-invasive cell tracking
in animal models and human patients that can be utilized for com-
panion diagnostics and monitoring.
Third, described cell selection processes and PEI pre-treatment are
easily applicable during cell production according to good
manufacturing practice and may also inform the development of
more specific, treatment-specific potency assays [8]. Moreover, the
techniques reported by Danielyan, Sch€afer and colleagues achieve
similar results than previously described lentiviral approaches [9],
but without the necessity for technically challenging or even perma-
nent cell modification. These features may ultimately foster clinical
translation of the approach.
Future research shall address some relevant open questions. For
instance, it should be carefully analysed whether the increased
migratory abilities are sufficient to increase migratory efficacy over
the relatively long distances to or within the human brain. Large
animal models, which are increasingly used in neurovascular andneurodegenerative research [10], may be helpful in this regard. Large
animal brain size and anatomy are closer to the human one. More-
over, the larger volume and migration distances in the human brain
present additional challenges for cell tracking approaches. Thus,
research on more effective labelling and sensitive detection techni-
ques for swiftly migrating cells are recommended. Finally, long-term
investigations should confirm the excellent safety profile of tran-
siently modified MSCs and NSCs.
In summary, the presented work represents a major step in the
direction of practical implementation of stem cell therapies for CNS
disorders in humans and may inform the development of functionally
improved cell products for that purpose.
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